Source comparison
CJC-1295 vs Alternative Sleep-Research Peptides: Evidence Comparison
CJC-1295 (with DAC) GHRH receptor agonist Animal models show 18–23% SWS increase; human trials measure GH/IGF-1 only 6–9 days per injection None published. Mechanistic inference only MK-677 (Ibutamoren) Ghrelin receptor agonist Human RCTs show 50% REM increase
This comparison does not assign a generated winner or score.
- CJC-1295 (with DAC)
- GHRH receptor agonist
- Animal models show 18–23% SWS increase; human trials measure GH/IGF-1 only
- 6–9 days per injection
- None published. Mechanistic inference only
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist
- Human RCTs show 50% REM increase, 20% REM density increase (Copinschi et al., 1997)
- 24-hour half-life, daily dosing required
- Multiple polysomnography trials confirm REM and SWS changes
- GHRP-2
- GH secretagogue receptor agonist
- Rodent models show SWS extension; no human sleep trials
- 20–30 minutes (requires multiple daily doses)
- None. Used for acute GH testing, not sleep
- Hexarelin
- No sleep-specific trials; GH pulse research only
- 60–90 minutes
- None
- MK-677 has the strongest direct sleep evidence but requires daily administration and carries ghrelin-mediated hunger as a side effect. Problematic for protocols where caloric intake needs control. CJC-1295's weekly dosing offers convenience and avoids appetite disruption, but the sleep benefit remains theoretical rather than polysomnography-confirmed. For labs prioritizing evidence strength over dosing convenience, MK-677 is the better-supported choice. For protocols where GH modulation is the primary goal and sleep is a secondary hypothesis, CJC-1295 fits.